Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Issued (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Shares Issued for 15 consecutive years, with $37.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 273.0% year-over-year to $37.3 million, compared with a TTM value of $129.4 million through Dec 2025, up 5.98%, and an annual FY2025 reading of $129.4 million, up 5.98% over the prior year.
  • Shares Issued was $37.3 million for Q4 2025 at Neurocrine Biosciences, down from $45.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $69.9 million in Q1 2024 and bottomed at $2.9 million in Q2 2023.
  • Average Shares Issued over 4 years is $25.5 million, with a median of $18.8 million recorded in 2023.
  • Peak annual rise in Shares Issued hit 752.44% in 2024, while the deepest fall reached 71.75% in 2024.
  • Year by year, Shares Issued stood at $15.2 million in 2021, then surged by 132.89% to $35.4 million in 2023, then crashed by 71.75% to $10.0 million in 2024, then surged by 273.0% to $37.3 million in 2025.
  • Business Quant data shows Shares Issued for NBIX at $37.3 million in Q4 2025, $45.6 million in Q3 2025, and $14.4 million in Q2 2025.